- Brown University
- Yale University
- Yale University
- Brigham and Women's Hospital
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
- Whitehead Institute for Biomedical Research
Awards & Honors
- 1993 Wilbur Downs Memorial International Health Fellowship, Yale University
- 1998 Lauri Strauss Leukemia Foundation Fellow
- 1998 William Guy Forbeck Foundation Fellow
- 2005 ASCI/AAP Travel Scholarship
- 2017 The Joseph and Ray Gordon Chair in Clinical Oncology and Research
- Creating a new drug to treat serious blood infections and their antibiotic-resistant biofilms;
- Studying a new immunotherapy for acute myeloid leukemia and pancreatic cancer;
- Developing methods for rapid response development of anti-viral drugs for epidemic viral illness.
The immune system provides constant surveillance to protect against infectious diseases, toxin exposures, and cancers. Part of the immune response is in the form of antibodies that are produced by B-cells. Through highly specific interactions, antibodies can neutralize infectious entities and possibly help combat tumor cells. Many technologies exist to clone human antibodies. The Dessain group's primary interest is in “native” human antibodies, those cloned and expressed in exactly the configuration created by the intact human immune system. Native human antibodies have the potential advantages of high affinity, minimal off-target binding, safety, and effectiveness.
The Dessain group has developed a highly effective method to clone native human antibodies, using only small amounts of blood that can be obtained by a normal blood draw from volunteers. In their method, they isolate B-cells from peripheral blood and convert them to hybrid cells that can be grown in culture, each expressing a single, unique antibody. Similar methods have been developed by others, but the Dessain group's method is very effective because of a unique fusion cell line that allows the high efficiency creation of stable hybrid cells, combined with a unique B-cell selection/expansion step. Thus far, they have produced antibodies reactive with botulinum neurotoxin, which can be used to treat food poisoning or counteract an act of bio-terrorism. They are also creating antibodies that may be potent therapeutics for other infectious diseases, neurological disease and cancer. For more on Dr. Dessain's research view the cover story in the Spring-Summer 2018 edition of Catalyst magazine.
Many laboratories have limited ability to generate their own human antibodies. In order to collaborate in cloning human antibodies with other investigators, the Dessain group has established the LIMR-Center For Human Antibody Technology. The LIMR-CHAT currently has collaborations underway with researchers at the University of Pennsylvania, Thomas Jefferson University, the Fox Chase Cancer Center, Salus University, Temple University, and Trinity College, Dublin, Ireland. They are actively seeking additional academic collaborations.
The human monoclonal antibody technology has been licensed to a start-up company, Immunome, Inc., which is located at the Incubator facility of the Lankenau Institute for Medical Research and is affiliated with the 611 Keystone Innovation Zone of Southeastern Pennsylvania. Immunome, Inc. can provide antibody cloning services on a commercial basis to industrial customers and/or collaborators.
- Fetweh Al-Saleem, DVM, Research Assistant Professor
- Chandana Devi Kattala, Biomedical Research Assistant
- Rama Devudu Puligedda, Biomedical Research Assistant
- Universal ELISA for quantification of D-antigen in inactivated poliovirus vaccines. Kouiavskaia D, Devudu Puligedda R, Dessain SK, Chumakov K. J Virol Methods. 2019 Nov 22:113785.
- Capture and display of antibodies secreted by hybridoma cells enables fluorescent on-cell screening. Puligedda RD, Sharma R, Al-Saleem FH, Kouiavskaia D, Velu AB, Kattala CD, Prendergast GC, Lynch DR, Chumakov K, Dessain SK. MAbs. 2019 Feb 22:1-13.
- Palliative Care in Lung Cancer: When to Start. Bhattacharya P, Dessain SK, Evans TL. Curr Oncol Rep. 2018 Nov 9;20(11):90. Review.
- Membrane-bound and soluble forms of an NMDA receptor extracellular domain retain epitopes targeted in auto-immune encephalitis. Sharma R, Al-Saleem FH, Puligedda RD, Rattelle A, Lynch DR, Dessain SK. BMC Biotechnol. 2018 Jun 27;18(1):41.
- Monoclonal antibodies from a patient with anti-NMDA receptor encephalitis. Sharma R, Al-Saleem FH, Panzer J, ... Cox RH, Dessain SK. Annals of Clinical and Translational Neurology. 2018 Jul 5.
- RBC Adherence of Immune Complexes Containing Botulinum Toxin Improves Neutralization and Macrophage Uptake. Al-Saleem FH, Sharma R, Puligedda RD, Elias M, Kattala CD, Simon PM, Simpson LL, Dessain SK. Toxins. 2017 May 19;9(5). pii: E173.
- Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes. Puligedda RD, Kouiavskaia D, Al-Saleem FH, Dessain SK, et al. Vaccine. 2017 Mar 23.
- Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains. Puligedda RD, Kouiavskaia D, Adekar SP, Sharma R, Devi C, Rezapkin G, Bidzhieva B, Dessain SK, Chumakov K. Antiviral Res. 2014. 108C:36-43.
- Mechanisms of enhanced Neutralization of Botulinum Neurotoxin by Monoclonal Antibodies Conjugated to Antibodies Specific for the Erythrocyte to Complement Receptor. Sharma R, Zhao H, Al-Saleem FH, Ubaid AS, Puligedda RD, Segan AT, Lindorfer MA, Bermudez R, Elias Md, Adekar SP, Simpson LL, Taylor RP, and Dessain SK. Mol Immunol. 2014. 57(2):247-254.
- A novel site-II directed glycoprotein estimation ELISA to aid rabies vaccine manufacture for veterinary and human use. Abhinay G, Dessain S, Srikanth A, Senthilkumar RL, Vidyasagar P, Praveen A, Chandrasekhar Reddy RV, Swapna Reddy E, Rajendra L. Vaccine. 2014. 32(2):209-13.